Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Corticotropin-releasing factor (CRF), also known as corticotropin-releasing hormone (CRH) or corticoliberin, is a 41-amino acid peptide hormone and neuropeptide that plays a central role in the body’s response to stress. It is primarily produced in the paraventricular nucleus of the hypothalamus and acts as the main driver of the hypothalamic–pituitary–adrenal (HPA) axis. Dysregulation of CRF is implicated in various psychiatric disorders and other conditions. CRF exerts its effects through two main receptor types: CRHR1 and CRHR2.
CRF antagonists block CRF receptors (CRHR1 and CRHR2), inhibiting the downstream effects of CRF on the HPA axis and other physiological processes.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Corticotropin-Releasing Factor (CRF).